The debut of troglitazone, a potent insulin-sensitizing agent, marked a notable chapter in the treatment of type 2 diabetes. However, its removal from the market due to substantial hepatotoxicity spurred broad investigation into related thiazolidinediones. Later pioglitazone and rosiglitazone emerged, offering similar mechanisms of action – prima